Nitric oxide (nitrogen monoxide; NO) is an important messenger molecule in various cell types, e. g. endothelial cells [1] , neurons [2] , or T lymphocytes [3] . However, when produced in large amounts and over prolonged periods of time, e. g. by macrophages [4] , NO is cytotoxic.
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Summary Nitric oxide (nitrogen monoxide, NO) acts as a signal transducer in a variety of cells. In the present study rat pancreatic islets were perifused with physiologically relevant glucose concentrations in the presence or absence of various NO-modulating agents. Perifusion in the presence of 0.1±1 mmol/l of the NO synthase inhibitor, N G -monomethyl-L-arginine or of 10 mmol/l of the NO-scavenger, 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (carboxy-PTIO), resulted in an inhibition of the early phase of glucose-stimulated insulin secretion by 60±65 % and 46 %, respectively. Light-and electron-microscopic studies revealed that pancreatic islets constitutively express NO-synthase in alpha and delta cells, where it is confined to the secretory granules. Therefore, these data indicate that NO may be important in the signal transduction pathway of the early phase of glucose-stimulated insulin secretion.
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stimulates insulin secretion from INS-1 cells by inducing calcium release from mitochondria [11] .
The site of NO production, mainly analysed by the immunohistochemical localization of NOS, in the pancreatic islets has not yet been identified. According to some authors NOS is present in all islet cells [6, 12] while others failed to detect NOS immunoreactivity in pancreatic islets and beta cells [13±15] . Therefore, our study also aimed to analyse the location of NOS in the isolated rat islet model.
In the present study we provide evidence that the immediate glucose-induced insulin secretion from pancreatic islets requires the formation of NO, and that NO may be formed by a constitutively expressed NOS located in the vascular endothelium and islet alpha-and delta-cells.
Materials and methods
Materials. Collagenase A from Clostridium histolyticum was purchased from Boehringer Mannheim (Rotkreuz, Switzerland); culture medium RPMI-1640 and newborn calf serum (NCS) were from Gibco (Basel, Switzerland); rat insulin was from Novo Nordisk (Bagsvaerd, Denmark).
and 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (carboxy-PTIO) were from Calbiochem (Luzern, Switzerland).
For immunohistochemistry the following antisera were used: antiserum SA-201 (Lot No: T3103; Biomol; Plymouth Meeting Penn., USA) raised in rabbit against endothelial NOS (eNOS); antiserum A 564 against insulin (Dako, Copenhagen, Denmark); antiserum 017060 against glucagon (Bioscience, Emmenbrücke, Switzerland); antiserum NT 116 against somatostatin (Eugene Tech, New Jersey, USA); antiserum 615-R110-146-6 against pancreatic polypeptide (Dr. R. Chance, Indianapolis, Ind., USA). For detailed information on the antisera see Reference [16] .
All other chemicals were of the highest purity commercially available.
Islet isolation and culture. Rat islets were isolated from collagenase-treated pancreata of newborn male and female (4±5 days old) Zur:SD rats and precultured in RPMI-1640 (containing 11 mmol/l glucose) + 10 % NCS. After 4 days, islets were washed and cultured for 2 days in RPMI-1640 + 1 mg/ml human serum albumin.
Perifusion protocol. Batches of 50 islets were placed in a perifusion chamber with a volume of 300 ml and perifused with Krebs-Ringer buffer at a flow rate of 600 ml per min.
During the first 49 min islets were perifused with 1.6 mmol/ l glucose. From min 49 to 59 the test substance was added to the perifusion medium (e. g. l-NMMA). At min 59 the glucose concentration was raised to 16 mmol/l for a period of 40 min (min 59±99), with the test substance still present. Thereafter (min 99±106), the glucose concentration was again lowered to 1.6 mmol/l. Fractions of the perifusate were collected each minute for determination of insulin. Insulin was measured with a competitive ELISA technique using rat insulin as standard [17, 18] . The detection limit was 0.1 ng/ml. The intraand interassay coefficient of variation was 6 and 9 %, respectively.
Immunohistochemical studies. Rat islets isolated as described above were fixed in a solution containing freshly made 2.5 % paraformaldehyde, 0.1 % glutardialdehyde and 0.01 % picric acid for about 4 h at room temperature. Thereafter, specimens were dehydrated in an ascending series of ethanol and routinely embedded in LR White (Polysciences, Warrington, PA., USA).
Light microscopy: Semithin sections (1.5 mm) were cut with a Reichert-Jung Ultracut E (Reichert-Jung, Zürich, Switzerland) and treated with phosphate-buffered saline containing 2 % bovine serum albumin and 2 % normal goat serum to reduce unspecific binding. For analysis of the coexistence of classical islet hormones and NOS, four consecutive sections were incubated consecutively for double immunofluorescence: the first section was incubated with the rabbit pancreatic polypeptide-antiserum, the second with the rabbit eNOS-antiserum (SA-201) and with the guinea pig insulin-antiserum, the third with the eNOS-antiserum and the mouse glucagon-antiserum, and the fourth with the eNOS-antiserum and the rat somatostatin-antiserum. Incubations were carried out for 12 h at 4 C. After buffer wash, the following secondary antisera were applied: biotinylated sheep anti-mouse IgG (Amersham International, Amersham, UK, 1 : 100) for the mouse glucagon-antiserum, biotinylated goat anti-guinea pig IgG (Bioscience Products, Emmenbrücke, Switzerland; 1 : 100) for the insulinantiserum and biotinylated sheep anti-rat IgG (Amersham, 1 : 100) for the rat somatostatin antiserum. Visualization was obtained with streptavidin-Texas-Red (Amersham, 1 : 50). For the detection and visualization of the rabbit antisera against eNOS and pancreatic polypeptide, fluorescein-isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Bioscience Products, 1 : 40) was used. Photomicrographs were taken with a Zeiss Axiophot (Zeiss, Zürich, Switzerland). For photography, the fluorochromes were visualized with fluorescence modules for FITC (BP 450±490 nm, FT 510, LP 515±565 nm) and for Texas-Red (BP 546, FT 580, LP 590 nm). Examination of co-existence was mainly carried out using a FITC/Texas-Red module (BP 485/20 546/12, FT 500/560, LP 515±530/580±630).
Electron microscopy: Ultrathin sections were cut with a Reichert-Jung Ultracut E. Sections were treated with 50 mmol/l gelatine in 10 ml phosphate buffered saline (PBS) containing 0.2 g bovine serum albumin and rinsed in PBS. For single staining, sections were incubated with antiserum SA-201 (1 : 500) overnight. After repetitive washing in PBS, anti-rabbit biotin (1 : 50) was applied to the sections for 1 h at room temperature. After washing in PBS, a 10 nm sized streptavidin-gold complex (1 : 50, Amersham was applied for 3 h at room temperature. For double staining, sections were incubated with NOS-antisera (1 : 200) and the mouse glucagon-antiserum (1 : 700). After repetitive washing in PBS, anti-mouse biotin labelled with 5 nm sized gold particles (1 : 25) and anti-rabbit biotin (1 : 25) were applied to the sections for 1 h at room temperature. After washing in PBS, a 15 nm sized streptavidingold complex (1 : 50, Amersham) was applied for 1 h at room temperature. Sections were rinsed in distilled water, air-dried and counterstained with uranyl acetate for 4 min. Sections were examined with a Philips EM 420 electron microscope.
Specificity controls: The specificity of the reactions obtained was tested using the following controls: 1) replacement of the primary antiserum by pre-immune or non-immune serum. 2) Preabsorption of the primary antisera with homologous and heterologous antigens at 5±500 mg/ml of antiserum.
Preabsorption of antiserum SA-201 with synthetic eNOS at a concentration of 10 mg/ml completely abolished staining. In contrast, preabsorption of antiserum SA-201 with synthetic glucagon or somatostatin did not influence immunoreactions. Reactions obtained by the antisera against the islet hormones could be abolished only by preabsorption with the respective antigen (10 mg/ml), but were still present after preabsorption with synthetic eNOS at concentrations as high as 500 mg/ml.
Morphometric analysis: Two independent observers blinded to the protocol evaluated both distribution and intensity of NOSimmunoreactivity in the 28 islets investigated by double immunofluorescence.
At the subcellular level, quantitative morphometry was performed additionally. Two independent observers blinded to the protocol counted the NOS-immunogold grains in the following areas: secretory granules, extragranular cell compartment and extracellular space. The procedure was applied for alpha-, beta-, delta-and PP-cells as well for endothelial cells. Countings were carried out on prints at a magnification of 23000 using a transparent sheet with 1 nm 2 squares.
Statistical analysis. Only perifusion experiments with islets from different isolations were considered as separate experiments. The areas under the curve (AUC) for the first and the second phase were compared separately. For calculation the first phase was defined from the earliest time point with an increased insulin secretion after the glucose stimulus until the time point with the lowest insulin level after the first peak. Thereafter, the second phase commenced lasting until the end of the glucose stimulation. In the figures, the beginning and the end of the first phase are marked with arrows. Data were analysed using the Wilcoxon matched pairs test. P less than 0.05 was considered significant. Perifusion studies. Rat islets perifused with buffer containing 1.6 mmol/l glucose secrete little insulin, i. e. 5±10 pg/islet min. Increasing the ambient glucose concentration from 1.6 to 16 mmol/l results in a typical biphasic pattern of insulin secretion (Fig. 1) . The first phase starts roughly 2 min after the increase of the glucose concentration and lasts for approximately 9 min. The second phase is characterized by a sustained insulin release with slow oscillations with a frequency of 7 to 10 min.
The NOS inhibitor, l-NMMA [19] , at a concentration of 0.5 mmol/l had no influence on insulin secretion at low ambient glucose, but markedly (by 62 %) inhibited the first phase of high glucose-stimulated insulin secretion (Fig. 1 A) . Thus, the AUC for the first phase was 42.9 ± 3.7 pg/islet min and 16.3 ± 3.1 pg/islet min in controls and l-NMMA-exposed islets, respectively (p < 0.05). The second phase was not altered by l-NMMA, the AUC being 44.6 ± 3.9 pg/islet min and 46.1 ± 8.6 pg/islet min in controls and l-NMMA-exposed islets, respectively.
The enantiomer d-NMMA, which does not inhibit NOS [20] , was used as control. As shown in Figure 1 B , 0.5 mmol/l d-NMMA had no effect on insulin secretion, the AUC for the first phase being 42.9 ± 3.7 pg/islet min and 39.8 ± 2.1 pg/islet min in controls and d-NMMA-treated islets, respectively, and for the second phase 44.6 ± 3.0 pg/islet min and 52.3 ± 4.5 pg/islet min controls and d-NMMAtreated islets, respectively.
Significant inhibition of the first phase of insulin secretion was achieved with l-NMMA concentrations of 0.1±1 mmol/l (Table 1) , while 5 mmol/l had no inhibitory effect. Addition of 10 mmol/l carboxy-PTIO, an NO scavenger [21] , to the perifusion medium resulted in an inhibition by 46 % of the first phase of insulin secretion (Fig. 2) . The AUC was 42.5 ± 6.9 pg/islet min and 23.3 ± 5.1 pg/islet min in controls and carboxy-PTIO-exposed islets, respectively (p < 0.05). The second phase was not affected, the AUC being 40.7 ± 8.3 pg/islet min and 38.4 ± 12.4 pg/islet min in controls and carboxy-PTIO-exposed islets, respectively.
Immunohistochemistry. We subjected 28 islets from 4 different isolates to light-microscopical and 8 islets to electron-microscopical immunohistochemistry. NOS-immunoreactivity was observed in all islets investigated and was located in cells of the vascular endothelium and in islet cells. In the electron-microscope, the endothelial cells showed immunogold labelling dispersed over the cytoplasm (Fig. 3) . NOSimmunoreactive islet cells were mainly at the islet periphery (Fig. 4) but occasionally also randomly distributed throughout the islets. NOS-immunoreactivity was mainly found in the alpha-, i. e. glucagon-immunoreactive cells (Figs. 3 and 4 ) and in the delta-, i. e. somatostatin-immunoreactive cells (Fig. 4) but not in beta-, i. e. insulin-immunoreactive cells. In all islets investigated NOS-immunoreactive alpha-and delta-cells were present although their relative numbers varied among the islets. The percentage of alpha-and delta-cells containing NOS-immunoreactivity ranged from 20 to 100 % with an average of 65 % (alpha-cells) and 76 % (delta-cells), respectively (Table 2) . At the subcellular level, NOS-immunoreactivity was confined to the secretory granules of both alpha-and delta-cells (Fig. 3, Table 3 ) and in the cytoplasm of endothelial cells. The faint immunogold staining observed in the granules of some beta and PP cells as well as in the extragranular cell compartment (Table 3 ) most likely represents background reactivity but may also reflect sensitivity differences between immunofluorescence and the immunogold technique. 
Discussion
Perifusion of rat islets with the NOS inhibitor l-NMMA, but not with its inactive enantiomer d-NMMA acutely inhibits the early phase of glucosestimulated insulin release, the maximal inhibition being observed with concentrations of 0.1±1 mmol/l of l-NMMA. Inhibition is also achieved with the NOscavenger carboxy-PTIO. These findings provide compelling evidence that NO is involved in the regulation of the early phase of glucose-stimulated insulin secretion and support the notion that NO plays a role in the secretagogue-induced signal transduction in rat pancreatic islets. Our findings corroborate some previously published data. Schmidt and co-workers [6] found with HIT cells that l-arginine-induced insulin release in the presence of glucose is partly mediated by NO. Laychock et al. [7] incubated isolated rat islets for 20 min with l-NMMA and demonstrated that glucose-and l-arginine-stimulated insulin release depends partly on the endogenous formation of NO and cGMP. Furthermore, continuous infusion of glucose together with a NOS inhibitor into conscious calves resulted in reduced plasma insulin and elevated plasma glucose concentration [22] .
However, a number of studies seem to argue against a stimulatory effect of NO on insulin secretion. Thus, incubation of islets for 30 min with an NOS inhibitor did not result in a detectable inhibition of insulin release [8] . Since in these experiments accumulated insulin was measured possible changes of the early insulin secretory phase may have been masked. In anaesthetized rats [23] or with chronic administration of N G -nitro-l-arginine-methyl ester (l-NAME) to rats [24] no significant effects of NOS inhibition on insulin release could be observed. Similarly, perfusion of rat pancreata with 5 mmol/l l-NAME had no effect on insulin secretion, while on the other hand perfusion with 5 mmol/l l-NMMA resulted in increased insulin levels [25] . These experiments are, however, difficult to compare with our perifusion system since in vivo administration or pancreas perfusion with NOS inhibitors may exert additional systemic effects such as vasoconstriction [23] or interfere with neuronal mechanisms which could affect insulin release [26] . Furthermore, NOS inhibition may also cause an increase in islet capillary blood flow [27] .
Recent studies suggest that l-arginine-derived NO may even suppress insulin release, since addition of l-NAME to the incubation medium resulted in an increase of insulin release [12, 28, 29] . However, in these studies a very high concentration of l-NAME (5 mmol/l) was used. According to Drews et al. [30] such a high concentration of l-NAME depolarizes the beta cell similarly to l-arginine and may trigger insulin release. Such an effect could explain why also in the present study 5 mmol/l of l-NMMA did not inhibit glucose-induced insulin secretion any longer. A severely impaired glucose-induced insulin secretory capacity was also observed after a 48 h exposure of rat islets to 4.5 mmol/l aminoguanidine, another NOS inhibitor [31] . At this concentration aminoguanidine may be toxic to pancreatic islets [31] .
The demonstration that endogenously produced NO participates in the signal transduction pathway of insulin secretion warrants the search for the presence of NO producing cells within the islets. Whether pancreatic islets, particularly the endocrine islets, constitutively express NOS is still a matter of discussion. Some investigators described NOS-immunoreactivity and/or NADPH-diaphorase staining in the majority of rat and mouse islet cells [6, 12] , whereas others failed to detect NOS-immunoreactivity in human and rat islets [13±15] . Apart from the important influence of the fixation procedures used [14, 15] and species differences, the existence of local isoforms of NOS may account for the observed discrepancies [15] .
The present study confirms the presence of NOSimmunoreactivity in the endocrine pancreas. The NOS-immunoreactivity, as assessed by immunofluorescence was confined to alpha cells and some delta cells and was not detectable in beta cells, while with the immunogold technique faint staining was also observed in some beta and PP cells. The finding that delta cells constitutively express NOS is an accordance with recent data obtained with murine and human pancreases [32] . To our knowledge, the presence of NOS in alpha cells has not been reported so far.
Our immunocytochemical studies demonstrating that NOS-immunoreactivity is mainly confined to the secretory granules of alpha and delta cells, represent the first ultrastructural localization of the enzyme in cells of the endocrine pancreas. The subcellular localization of NOS in endocrine islet cells is in accordance with recent reports describing NOS in secretory granules of gastric D-cells [32] and in synaptic vesicles of enteric neurons [33] .
The presence of NOS-immunoreactivity in the secretory granules may indicate the production and subsequent diffusion of NO from alpha and delta cells to beta cells. The effects of NO on glucose-stimulated insulin release from beta cells under physiological conditions could, therefore, be exerted in a paracrine manner by neighbouring alpha and/or delta cells or by endothelial cells. However, since we only looked for eNOS-immunoreactivity we cannot exclude that other isoforms of the enzyme, e. g. nNOS or iNOS may be expressed in the beta cells themselves. Further studies including Western blot analysis and assessment of enzyme activity in different islet cell types are needed, particularly since faint immunogold staining for NOS was also seen in some beta and PP cells.
The mechanism by which NO triggers insulin release remains to be elucidated. There are different possibilities which warrant further investigation: NO could mobilize Ca 2+ from the endoplasmic reticulum as recently demonstrated in sea urchin eggs by Willmott et al. [34] or from the mitochondrial Ca 2+ pool [11, 35] . Another possible target for NO could be the insulin vesicle, since in synaptosomes NO modulates synaptic vesicle docking fusion reactions [36] . Finally, NO could interact with some receptors on the beta cell surface or with ion channels as was suggested for neurons [37±41] .
In summary, the data presented here show that the early phase of glucose-stimulated insulin secretion is at least partly mediated by NO which could be produced in islet alpha and delta cells. Data are mean ± SEM NE, Non-existent Islets were analysed as described in Materials and Methods
